Tranimilast
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Tranimilast
- Molecular weight
- 687.54
- Structure (SMILES)
- CS(=O)(=O)Nc1ccc(C(=O)O[C@@H](Cc2c(Cl)c[n+]([O-])cc2Cl)c2ccc(OC(F)F)c(OCC3CC3)c2)cc1OCC1CC1
- chf 6001
- CHF 6001
- Chf-6001
- chf6001
- Chf6001
- CHF6001
- chf6001 3200µg
- CHF6001 3200µg
- j3 309 618f
- J3.309.618F
- tanimilast
- Tanimilast
- tanimilast [INN]
- tanimilast inn
- tranimilast
- Tranimilast
- TRANIMILAST [USAN]
- tranimilast usan
- CAS registry numbers
- 1239278-59-1
- ChEMBL ID
- CHEMBL3113974
- InChIKey
- VCFBPAOSTLMYIV-SANMLTNESA-N
- PubChem compound IDs
- 70662473
- FDA ingredient codes (UNII)
- 0984EU6E2F
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -ast
- Mechanism
- Phosphodiesterase 4 inhibitor
- Action type
- Inhibitor
- Target
- Phosphodiesterase 4
- Protein identifier
- P27815
- Mechanism
- Phosphodiesterase 4 inhibitor
- Action type
- Inhibitor
- Target
- Phosphodiesterase 4
- Protein identifier
- Q07343
- Mechanism
- Phosphodiesterase 4 inhibitor
- Action type
- Inhibitor
- Target
- Phosphodiesterase 4
- Protein identifier
- Q08493
- Mechanism
- Phosphodiesterase 4 inhibitor
- Action type
- Inhibitor
- Target
- Phosphodiesterase 4
- Protein identifier
- Q08499
Open Targets mechanisms
- Mechanism
- Phosphodiesterase 4 inhibitor
- Action type
- Inhibitor
- Target
- Phosphodiesterase 4
- Condition
- Pulmonary Disease, Chronic Obstructive
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000341
- Subject identifier
- D029424
- Condition
- Asthma
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0004979
- Subject identifier
- D001249
- Condition identifier
- EFO_0000341
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0004979
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005002
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005607
- Highest recorded phase
- 3
- NCT01689571
- NCT01730404
- NCT02986321
- NCT03004495
- NCT04739774
- NCT04756960
- NCT05373953
- NCT06395610
- Hydrogen bond acceptors
- 8
- Hydrogen bond donors
- 1
- Polar surface area
- 127.1
- Calculated partition coefficient (ALogP)
- 6.32
- Calculated partition coefficient (XLogP)
- 5.8
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 2
- Rotatable bonds
- 15
- Heavy atoms
- 45
- Molecular formula
- C30H30Cl2F2N2O8S
- Monoisotopic mass
- 686.1067988
- Natural product
- No
- Recorded assays
- 46
- Active assays
- 12
Active assay types
- Confirmatory
Distribution coefficient (LogD)
- Median
- 4.48
- Mean
- 4.48
- Minimum
- 4.48
- Maximum
- 4.48
- Unit
- unitless
- Assays
- 1
- Standard deviation
- 0
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- LogD
Plasma protein binding
- Median
- 99.59
- Mean
- 99.59
- Minimum
- 99.2
- Maximum
- 99.98
- Unit
- %
- Assays
- 2
- Standard deviation
- 0.551543
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- PPB
Related records
Trials (14)
- A 24-wk Dose Ranging Study to Evaluate the Efficacy and Safety of 4 Doses of a New PDE4 Inhibitor in Patients With COPD
- A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR)
- A 52-week, Placebo-controlled Study to Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis (PILASTER)
- A Comparison Study Between Adolescents With Asthma and Adults With Asthma on How They Absorb, Metabolise and Eliminate CHF 6001
- A Study to Evaluate the Efficacy After Allergen Challenge, Safety and Tolerability of Inhaled CHF6001 DPI in Asthmatics
- Clinical Study to Investigate the Pharmacokinetics, Safety and Tolerability Following Single Administration of CHF6001 in Subjects With Mild, Moderate and Severe Liver Impairment in Comparison With Matched Healthy Control Subjects
- Effect of Cyclosporine Drug Interaction on the Absorption, Metabolism and Elimination of CHF6001 in Healthy Volunteers. Drug-Drug Interaction 2 (DDI2) Study
- Effect of Erythromycin on the Absorption, Metabolism and Elimination of CHF6001 in Healthy Volunteers
- Efficacy and Safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund Maintenance Therapy
- Evaluation of the Absolute Bioavailability and Mass Balance of CHF6001 (Tanimilast) in Healthy Subjects
- Investigation of the Effect of Inhibition of CYP3A4/5 by Itraconazole on the PK of CHF6001 (Tanimilast)
- Pharmacodynamics, Pharmacokinetics and Safety of Two Doses of CHF6001 DPI in Subjects With Moderate, Severe COPD
- Pharmacokinetic Interaction and the Safety of Inhaled CHF5259 and CHF6001
- Safety, Tolerability and Efficacy of 28-day Inhaled CHF 6001 DPI in COPD Patients
In development for (3)
- Asthma Phase 2
- Chronic bronchitis Phase 3
- Chronic obstructive pulmonary disease Phase 2